ライフサイエンスコーパス: monoclonal gammopathy

1 into bone marrow and the presence of an IgM monoclonal gammopathy.

2 inosis, extracutaneous manifestations, and a monoclonal gammopathy.

3 coni syndrome (FS) is a rare complication of monoclonal gammopathy.

4 from the sera of individuals with a form of monoclonal gammopathy.

5 for histology in patients who do not have a monoclonal gammopathy.

6 proportion of patients will have persistent monoclonal gammopathy.

7 or hereditary amyloidosis with a concomitant monoclonal gammopathy.

8 um and glutamate than patients with indolent monoclonal gammopathies.

9 by CD138(+) cells across the progression of monoclonal gammopathies.

10 n has been implicated in the pathogenesis of monoclonal gammopathies.

11 se-associated gammopathies and some sporadic monoclonal gammopathies.

12 Gaucher's disease have an increased risk of monoclonal gammopathies.

13 irus (EBV) replication in the persistence of monoclonal gammopathy.1 It has been known for some time

14 Further investigation revealed a monoclonal gammopathy, a unique patterning of subcutaneo

15 se characterized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms s

16 yeloma (CMM) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monocl

17 d and 2% of symptomatic patients) had both a monoclonal gammopathy and a hereditary variant.

18 a B-cell malignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration

19 Three (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrenc

20 We review the causal association between monoclonal gammopathy and neuropathy, and critically rev

21 fection is unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can

22 HIV infection have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The

23 o indicate a causal relationship between the monoclonal gammopathy and the renal damage and because t

24 me is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and b

25 ber of kidney diseases associated with other monoclonal gammopathies are being recognized.

26 Monoclonal gammopathies are frequently complicated by ki

27 The IgG and IgA monoclonal gammopathies are rarely associated with speci

28 IgD monoclonal gammopathies are uncommon.

29 gnificance (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy.

30 aracterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biol

31 characteristics of human disease, including monoclonal gammopathy, BM infiltration with lytic bone l

32 In patients with monoclonal gammopathies, C-reactive protein may be a mor

33 pared with 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 p

34 ion disease (MIDD) is a rare complication of monoclonal gammopathy characterized by deposition of mon

35 Certain human sera from patients with monoclonal gammopathies contain factors that induce myel

36 In conclusion, FS associated with monoclonal gammopathy does not appear to confer an addit

37 mune cells in 305 patients with asymptomatic monoclonal gammopathy enrolled in S0120 under the auspic

38 sed on clinical and laboratory findings with monoclonal gammopathy evaluation and, if indicated, TTR

39 ent of peripheral neuropathy associated with monoclonal gammopathies has been advanced by recent clin

40 ) and associated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ

41 phritic factor in child GP patients and with monoclonal gammopathy in adult GP patients, who frequent

42 The high frequency of monoclonal gammopathy in adult patients with C3 glomerul

43 a cell dyscrasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is

44 Monoclonal gammopathy in several patients may have poten

45 trosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy

46 onal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolip

47 e that clinical progression in patients with monoclonal gammopathies is associated with an acquired b

48 -stage renal disease, the persistence of the monoclonal gammopathy is associated with high rates of r

49 l damage and because the significance of the monoclonal gammopathy is no longer undetermined.

50 2 or more years before diagnosis to detect a monoclonal gammopathy (M-Ig).

51 A high prevalence of monoclonal gammopathy (MG) has been observed in HIV-infe

52 biopsy in only 15% of patients, included 21 monoclonal gammopathies of renal significance; 15 multip

53 l population can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MG

54 y modified paraprotein target (paratargs) in monoclonal gammopathies of undetermined significance (MG

55 from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) w

56 Recently, the term monoclonal gammopathy of renal significance (MGRS) was i

57 Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%),

58 We think the term monoclonal gammopathy of renal significance is most help

59 tion process of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) a

60 tribution was determined in 63 patients with monoclonal gammopathy of uncertain significance (MGUS) a

61 Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred

62 from 56 subjects representing premalignant (monoclonal gammopathy of uncertain significance), early,

63 performed CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 c

64 as an indolent course of disease that mimics monoclonal gammopathy of undermined significance, wherea

65 ltiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mo

66 34 patients with WM and 10 patients with IgM monoclonal gammopathy of undetermined significance (IgM

67 amples from 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-

68 Monoclonal gammopathy of undetermined significance (MGUS

69 ich evolves from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS

70 Monoclonal gammopathy of undetermined significance (MGUS

71 Monoclonal gammopathy of undetermined significance (MGUS

72 The transformation from monoclonal gammopathy of undetermined significance (MGUS

73 Monoclonal gammopathy of undetermined significance (MGUS

74 ilial clustering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS

75 We examined whether monoclonal gammopathy of undetermined significance (MGUS

76 pesticide applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS

77 IgM monoclonal gammopathy of undetermined significance (MGUS

78 Monoclonal gammopathy of undetermined significance (MGUS

79 in the etiology of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS

80 e marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS

81 ve cases of multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS

82 The factors that determine progression from monoclonal gammopathy of undetermined significance (MGUS

83 Monoclonal gammopathy of undetermined significance (MGUS

84 The prevalence of monoclonal gammopathy of undetermined significance (MGUS

85 21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS

86 (MM) are preceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS

87 Monoclonal gammopathy of undetermined significance (MGUS

88 thylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS

89 of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS

90 Monoclonal gammopathy of undetermined significance (MGUS

91 studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS

92 in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS

93 s of premalignant non-immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS

94 ppa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS

95 sorting exosomes from multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS

96 rease in CD4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS

97 Whether this dichotomy exists in monoclonal gammopathy of undetermined significance (MGUS

98 d for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS

99 receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS

100 ed in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS

101 The events leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS

102 At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS

103 Plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS

104 ression was detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS

105 been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS

106 A monoclonal gammopathy of undetermined significance (MGUS

107 previously untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS

108 Unlike monoclonal gammopathy of undetermined significance (MGUS

109 omal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS

110 ewly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS

111 arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS

112 al similarities to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS

113 V-8 may play a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS

114 ifferentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS

115 ic cells from two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS

116 e multiple myeloma to a benign form known as monoclonal gammopathy of undetermined significance (MGUS

117 g clonal cells in the blood of patients with monoclonal gammopathy of undetermined significance (MGUS

118 olves from a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS

119 peculated that the clinical progression from monoclonal gammopathy of undetermined significance (MGUS

120 M transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS

121 of multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS

122 n premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS

123 onsistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS

124 Monoclonal gammopathy of undetermined significance (MGUS

125 Blood, Farr et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS

126 lonal gammopathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS

127 ressed in bones of a subset of patients with monoclonal gammopathy of undetermined significance (MGUS

128 Monoclonal gammopathy of undetermined significance (MGUS

129 In 728 Swedish cases of monoclonal gammopathy of undetermined significance (MGUS

130 esson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS

131 Patients with monoclonal gammopathy of undetermined significance (MGUS

132 was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS

133 Monoclonal gammopathy of undetermined significance (MGUS

134 old woman with AL-amyloidosis secondary to a monoclonal gammopathy of undetermined significance (MGUS

135 er in these patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS

136 Monoclonal gammopathy of undetermined significance (MGUS

137 demonstrate an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS

138 Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS

139 Monoclonal gammopathy of undetermined significance (MGUS

140 the original clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS

141 le myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS

142 The association of obesity with monoclonal gammopathy of undetermined significance (MGUS

143 istently preceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS

144 nce interval [CI], 1.31-17.86; P = .018) and monoclonal gammopathy of undetermined significance (OR,

145 plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS

146 with the marrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined significance [MGUS

147 They are seen rarely as a monoclonal gammopathy of undetermined significance and a

148 ping phenotypic profiles between AL and both monoclonal gammopathy of undetermined significance and M

149 indeterminate potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and m

150 attern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at di

151 SMM is distinguished from monoclonal gammopathy of undetermined significance by a

152 those from healthy donors and patients with monoclonal gammopathy of undetermined significance or ot

153 icroenvironment cells in transformation from monoclonal gammopathy of undetermined significance or sm

154 ecreased serum adiponectin concentrations in monoclonal gammopathy of undetermined significance patie

155 in a pattern that parallels progression from monoclonal gammopathy of undetermined significance to MM

156 An IgG kappa monoclonal gammopathy of undetermined significance was f

157 Plasma cells in 10 patients with monoclonal gammopathy of undetermined significance were

158 n biomarkers can help identify patients with monoclonal gammopathy of undetermined significance who a

159 molecular characteristics that evolves from monoclonal gammopathy of undetermined significance, a hi

160 nguish POEMS from neuropathy associated with monoclonal gammopathy of undetermined significance, addi

161 h light chain amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance, and

162 progression from the non-malignant disorder monoclonal gammopathy of undetermined significance, are

163 ight chain amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance, immu

164 Preexisting plasma cell disorders, monoclonal gammopathy of undetermined significance, or s

165 er than in plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smol

166 evidence of paraproteinemia in a setting of monoclonal gammopathy of undetermined significance, smol

167 ong 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supp

168 e marrow myeloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.

169 apheresis have shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.

170 neuropathy, myeloproliferative disorder, and monoclonal gammopathy of undetermined significance.

171 ge-progressive premalignant condition termed monoclonal gammopathy of undetermined significance.

172 Monoclonal gammopathy of unknown significance (MGUS) and

173 0%) methylation of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had

174 ra from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PB

175 Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS su

176 but not in the limited plasma cell disorder monoclonal gammopathy of unknown significance or in nonm

177 onsecutive patients with multiple myeloma or monoclonal gammopathy of unknown significance sequential

178 tomatic MM, 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 in

179 monoclonal T-cell populations, analogous to monoclonal gammopathy of unknown significance.

180 in patients with indolent smoldering MM and monoclonal gammopathy of unknown significance.

181 iple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.

182 hat proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however,

183 The constellation of lambda-restricted monoclonal gammopathy, plasma cell rimming around lympho

184 Paraproteinemia relates to monoclonal gammopathy-producing pathologic antibodies wi

185 AL) and multiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular c

186 ficance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development o

187 IgG deposits, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomeru

188 Multiple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a

189 ith end-stage renal disease and known benign monoclonal gammopathy underwent kidney transplantation a

190 Monoclonal gammopathy was of IgG type in 47 (94%) patien

191 rdless of age, is frequently associated with monoclonal gammopathies, which often recognize various m